Fund moves

AbbVie (ABBV): British Columbia Investment Management Corp added to its stake +59K shares

British Columbia Investment Management Corp added to its stake in AbbVie, per its Q4 2025 13F.

313K
Shares reported · +59K vs prior quarter
0.38%
Disclosed portfolio weight
$71.6M
Reported value
Holdings as of
Dec 31, 2025
Filed
Feb 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2024CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  2. Jan 24, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  3. Apr 28, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  4. Dec 8, 2025Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $3.8K obligated to date
  5. Dec 8, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  6. Dec 12, 2025Federal contract · $24K obligatedDepartment of Defense awarded AbbVie: $24K obligated to date
  7. Dec 18, 2025FDAFDA drug approval: Vraylar
  8. Dec 18, 2025FDAFDA drug approval: Vraylar
  9. Dec 18, 2025FDAFDA drug approval: Vraylar
  10. Dec 18, 2025FDAFDA drug approval: Vraylar
  11. Dec 18, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  12. Dec 22, 2025Government · Federal Register noticeCertain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Institution of Investigation
  13. Jan 7, 2026Company filing · Form 8-K · ResultsReported its results
  14. Jan 16, 2026FDAFDA device clearance: Natrelle 133S Tissue Expanders
  15. Jan 20, 2026Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $4K obligated to date
  16. Feb 3, 2026Federal contract · $5K obligatedDepartment of Defense awarded AbbVie: $4.6K obligated to date
  17. Feb 4, 2026Company filing · Form 8-K · ResultsReported its results

What came next

  1. Feb 19, 2026FDAFDA drug approval: Venclexta
  2. Feb 25, 2026Insider · Their largest sale since 2023Officer sold ~$5.15M of ABBV shares in the open market
  3. Mar 2, 2026Insider · 1 personInsiders: 3 sales (~$4.4M)
  4. Mar 4, 2026InsiderOfficer sold ~$1.22M of ABBV shares in the open market
  5. Mar 5, 2026Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.4K obligated to date
  6. Mar 6, 2026FDAFDA drug approval: Skyrizi
  7. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
  8. Mar 9, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  9. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  10. Apr 3, 2026Company filing · Form 8-K · ResultsReported its results
  11. Apr 23, 2026Government · Federal Register noticeKimberly Schaff Kiehl: Final Debarment Order
  12. Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
  13. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  14. May 5, 2026CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  15. May 18, 2026FDARecall: PRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only, Allergen, Inc., an AbbVie company, North Chicago, IL 60064, Product…
  16. May 19, 2026Layoff notice · 2525 Dupont Drive Irvine CA 92612Layoff notice filed in CA: 85 employees
  17. May 20, 2026FDAFDA drug approval: Venclexta
  18. May 21, 2026FDAFDA drug approval: Linzess
  19. May 27, 2026FDAFDA drug approval: Decnupaz
  20. Jun 3, 2026Government · Federal Register noticeElite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for AbbVie

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

How this filing works

Explore the data

Common questions

What does this filing report about AbbVie (ABBV) stock?

British Columbia Investment Management Corp added to its stake in AbbVie, per its Q4 2025 13F. Now 313K shares, $71.6M reported value, 0.38% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Dec 31, 2025. Filed: Feb 13, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about AbbVie recently?

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABBV page.

Does this mean ABBV stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at AbbVie

Everything OQRO holds on this company is on its ABBV page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data